
RESEARCH ARTICLE: Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial @massnardone @DSchnekenB ahajrnls.org/4rhIcAj

PhD | CardioRenal

RESEARCH ARTICLE: Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial @massnardone @DSchnekenB ahajrnls.org/4rhIcAj

Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy? - The Lancet thelancet.com/journals/lance…

Beyond a singular focus on #GLP-1: why we need a new nomenclature now thelancet.com/journals/landi… multihormone receptor modulator (#MHRM)

RESEARCH ARTICLE: Establishing Reference Values for Pulse Wave Velocity in Young People: The Youth Vascular Consortium @RachelClimie @VimarshaHK @ProfRuanKruger @JeanneHersant @rosam_bruno @seanagall @alta_schutte @HanssenHenner @pierreboutouyr1 ahajrnls.org/3TihjgR

Research Article by @AndrLTeixeira3 et al. (@Millar_Lab @DrBurr @massnardone @JorB_L @uofg) Interindividual variability in #renal and #muscle #sympatheticresponses to #mentalstress: contributions to #bloodpressure regulation ow.ly/21BK50WeP85

These hard-working @UofG_HHNS authors are bringing us new #exercise research in this #ArticleinPress, Evidence for potentiation in sympathetic neurovascular transduction following exercise in normotensive adults (Massimo Nardone et al.): ow.ly/5qY350Wh47T

Presented at #ADASciSessions: In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body-weight reduction in adults without diabetes and with overweight or obesity. Full trial results: nej.md/444aW7f @ADA_DiabetesPro

Short Report by SE Hilton et al. (@massnardone @julianbommarito @Millar_Lab @uofg) Influence of #sex and #aerobicfitness on #bloodpressure during #maximal #treadmill #exercise in young healthy adults 🏃➡️ ow.ly/QhGU50VX2ef

Happy to share our new paper in @japplphysiol examining muscle sympathetic action potential firing after acute cannabis use pubmed.ncbi.nlm.nih.gov/4038…

That's a wrap! Thanks to everyone who joined us for our Annual Scientific Day at The Old Mill. Such a wonderful opportunity to network and learn.

Cardiovascular disease in chronic kidney disease CVD and CKD has a major impact on the prognosis of patients inflammation, anaemia, volume overload, and the presence of uraemic toxins : involvement of several pathophysiological mechanisms academic.oup.com/eurheartj/a…

New research from @TGHRI_UHN suggests #diabetes drugs dapagliflozin & empagliflozin may lower heart disease & kidney failure risk in people with #Type1Diabetes. Findings highlight the need for trials to confirm benefits ➡️ uhnresearch.ca/news/evaluati… #DiabetesResearch

Dapagliflozin improves estimated CVD and ESKD risk in T1D participants, emphasizing the need for cardiorenal outcome trials in people living with T1D. bit.ly/CJASN0641 @DrValRac @FrederikPersson #ASNCJASN

Upcoming drug targets for kidney protective effects in chronic kidney disease 🆓doi.org/10.1093/ndt/gfae216

Excited to share our contributions to a special supplement on combination therapy in chronic kidney disease @NDTsocial: Upcoming drug targets for kidney protective effects in chronic kidney disease academic.oup.com/ndt/article…

Check out our new series of reviews on CKD combination therapy in @NDTsocial academic.oup.com/ndt/issue/4…